Enzon Pharmaceuticals, Inc. Stock Other OTC
Equities
ENZN
US2939041081
Biotechnology & Medical Research
Financials (USD)
Sales 2022 | 26K | Sales 2023 | - | Capitalization | 6.94M |
---|---|---|---|---|---|
Net income 2022 | - | Net income 2023 | 1M | EV / Sales 2022 | -1,103 x |
Net cash position 2022 | 46.98M | Net cash position 2023 | 47.01M | EV / Sales 2023 | - |
P/E ratio 2022 |
-12.5
x | P/E ratio 2023 |
70.9
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.16% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 80 | 13-12-12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Randolph Read
CHM | Chairman | 71 | 20-08-03 |
Director/Board Member | 67 | 22-06-30 | |
Jordan Bleznick
BRD | Director/Board Member | 68 | 20-08-03 |
1st Jan change | Capi. | |
---|---|---|
-2.20% | 104B | |
+1.49% | 97.42B | |
+0.79% | 22.2B | |
-18.06% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-16.16% | 15.06B | |
+4.14% | 13.98B | |
+34.74% | 11.66B |